Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Novartis’ registration of head-to-head psoriatic arthritis clinical trial begins the battle for second place,

Novartis recently registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnson’s Stelara (ustekinumab). The registration of this trial demonstrates Novartis’ continued efforts to solidify its position in an increasingly crowded market, according to GlobalData, a leading data and analytics company. Tiffany Chan, Immunology Analyst […]
Read more

Bladder cancer therapeutics market projected to exceed $5.5bn by 2028

The bladder cancer therapeutics market was valued at $670m in 2018 across the seven major markets (7MM*) and is expected to grow exponentially at a compound annual growth rate (CAGR) of 23.6% – accruing slightly less than $5.6bn in 2028, according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Bladder Cancer Opportunity […]
Read more

Following landmark approval, Pfizer and BioNTech can use UK as test bed for cold chain distribution

Following the news that Pfizer/BioNTech’s COVID-19 vaccine BNT162b2 received emergency use approval from UK health authorities; Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “The UK represents an ideal test bed for the delivery of Pfizer’s vaccine. The country’s small size, dense population and strong […]
Read more

China pulls ahead in immuno-oncology with highest PD-1/PD-L1 combination clinical trials growth, reveals GlobalData

China recorded the highest year-on-year increase in the number of clinical trials initiated investigating PD-1/PD-L1 targeted combination immuno-oncology therapies across the eight major markets (8MM*) in 2020, according to GlobalData, a leading data and analytics company. In 2020, the US emerged as the leading market in industry-sponsored initiated clinical trials for PD-1/PD-L1 targeted combination therapies […]
Read more

Phase III data for Omecamtiv Mecarbil and Finerenone demonstrates reduced risk of cardiovascular events at AHA conference

A record number of late-breaking trials were submitted to the Annual Scientific Sessions of the American Heart Association (AHA) this year and unsurprisingly, a key theme of this year’s conference was the COVID-19 pandemic, says GlobalData, a leading data and analytics company. Fiona Chisholm, Managing Analyst at GlobalData, comments: “One notable study, which analyzed records […]
Read more

FDA approval of Provention Bio’s Teplizumab could bring first disease-modifying therapy to type 1 diabetes space

If Provention Bio’s rolling Biologic License Application (BLA) submission to the FDA for teplizumab is approved, teplizumab will be the first disease-modifying therapy for type 1 diabetes (T1D). Teplizumab is one of the first therapeutics to demonstrate a disease-modifying effect for T1D. As it is a prevention therapy, it is expected to encourage early screening […]
Read more

Biogen’s aducanumab in AD unlikely to be well-covered by payers, with FDA approval prospects mixed

Following a controversial FDA Advisory Committee meeting for Biogen’s aducanumab for mild Alzheimer’s disease, where the panel members sharply recommended against approval, the therapy will likely face significant barriers to coverage if it gains an agency nod in March, according to reporting from William Newton, Pharma Writer for the Investigative News team at GlobalData, a […]
Read more

Global IPF market set to reach $3.6bn by 2029

The idiopathic pulmonary fibrosis (IPF) market was valued at $2.5bn in 2019 across the seven major markets (7MM*), and is expected to grow to $3.6bn by 2029 with a compound annual growth rate (CAGR) of 3.8%, according to GlobalData, a leading data and analytics company. According to the company’s latest report: ‘Idiopathic Pulmonary Fibrosis: Opportunity Analysis […]
Read more
1 … 75 76 77 78 79 … 110